Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05977751 · ClinicalTrials.gov registry record · NA
Prospective Multi-Center Trial for FemBloc Permanent Birth Control
A NA study of Contraception, sponsored by Femasys.
- Recruiting
- Registry status
- NA
- Development phase
- 573
- Enrollment target
- 8
- Study locations
NCT05977751: Recruiting NA study of Contraception, sponsored by Femasys.
NCT05977751 is a NA study of Contraception that is actively recruiting participants, run by Femasys. The registered enrollment target is 573 participants, above the 447-participant average among 72 other Contraception trials with a reported enrollment target (28% higher). The trial reports 8 study locations across 7 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05977751, a NA study of Contraception, is actively recruiting participants, sponsored by Femasys.
- RECRUITING
- Registry status
- NA
- Development phase
- 573 participants
- Enrollment target
- 8
- Study locations
Study Summary
Prospective, multi-center, international, unblinded, single-arm trial of subjects undergoing FemBloc followed by ultrasound confirmation test.
Primary Outcome
Number of subjects who were told to rely on FemBloc for birth control and became pregnant through one (1) year.
Conditions Studied
Interventions
- DEVICE FemBloc
Study Locations (8)
California
- Stanford University - Palo Alto
- University of California Davis - Sacramento
Arizona
- New Horizons Clinical Trials - Chandler
Georgia
- Midtown OB GYN North - Columbus
Idaho
- Rosemark WomenCare Specialists - Idaho Falls
New York
- Maimonides Medical Center - Brooklyn
Ohio
- Seven Hills Women's Health Centers - Cincinnati
Utah
- University of Utah - Salt Lake City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 573 participants |
| Start Date | 2023-10-31 |
| Est. Completion | 2031-06 |
| Phase | NA |
What NCT05977751 shows while recruiting
NCT05977751 is an interventional study that assigns participants to a tested intervention. The registered 573 participants enrollment target is mid-sized for trials with a published cap, above the 447-participant average among 72 other Contraception trials with a reported enrollment target (28% higher).
The record links to 1 condition, with Contraception appearing as the primary indexed condition, and to 1 intervention - of which FemBloc is the first listed.
NCT05977751 lists 8 locations in 7 states (California, Arizona, Georgia).
Frequently Asked Questions
What is clinical trial NCT05977751 about?
NCT05977751 is a clinical study titled "Prospective Multi-Center Trial for FemBloc Permanent Birth Control". Prospective, multi-center, international, unblinded, single-arm trial of subjects undergoing FemBloc followed by ultrasound confirmation test.
What is the current status of trial NCT05977751?
This trial is currently recruiting. It is a NA study. The enrollment target is 573 participants. The study started on 2023-10-31. Estimated completion is 2031-06.
What conditions does trial NCT05977751 study?
This clinical trial studies the following conditions: Contraception.
What interventions are being tested in trial NCT05977751?
The interventions under investigation include: FemBloc (DEVICE).
Who is sponsoring clinical trial NCT05977751?
This trial is sponsored by Femasys, which has 5 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05977751 being conducted?
This trial has 8 study locations across Arizona, California, Georgia, Idaho, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Contraception
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05977751's enrollment target sits among peer trials
573 22nd of 72 higher than 51 of 72 other Contraception trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Contraception trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Patient-clinical Linkages to Improve Trust and Engagement in Postpartum Healthcare
RECRUITING · NA
-
Empathy Through Pain Control: Lidocaine Paracervical Block for IUD Placements
RECRUITING · NA
-
Hormonal Contraception Access Through Pharmacist Prescribing Implementation
RECRUITING · NA
-
Contraceptive Efficacy Study of Ovaprene
RECRUITING · NA
-
Intervening on Women's Health for Rural Young Cancer Survivors
RECRUITING · NA
-
Patient-centered Information on Permanent Contraception
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT07349537 · 574 participants · Phase 1
Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors
- NCT05131022 · 572 participants · Phase 1
A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies
- NCT06346392 · 572 participants · Phase 3
AZD0901 Compared With Investigator's Choice of Therapy in Participants With Second- or Later-line Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Expressing Claudin18.2
- NCT06615050 · 572 participants · Phase 3
A Study of Tacrolimus/Methotrexate/Ruxolitinib Versus Post-Transplant Cyclophosphamide/Tacrolimus/Mycophenolate Mofetil in Non-Myeloablative/Reduced Intensity Conditioning Allogeneic Peripheral Blood Stem Cell Transplantation (BMT CTN 2203)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI